Beauty Health Narrows Loss but Revenue Falls Again

The Beauty Health (SKIN) reported fiscal 2025 Q4 earnings on March 12, 2026. The company narrowed its net loss by 23.1% to $0.06 per share, while revenue fell 1.3% to $82.37 million. Guidance for 2026 revenue remained flat year-over-year, reflecting stabilization efforts amid macroeconomic pressures.

Revenue

The Beauty Health’s total revenue declined 1.3% year-over-year to $82.37 million in Q4 2025. Consumables revenue, a key recurring income stream, rose 1.7% to $57.7 million, driven by higher treatment spend and pricing actions. Conversely, device revenue contracted 7.9% to $24.7 million, reflecting persistent challenges in the capital equipment segment. The shift toward consumables aligns with the company’s strategy to leverage its installed base of over 36,000 systems globally.

Earnings/Net Income

The company reduced its net loss to $8.10 million in Q4 2025, a 21.5% improvement from $10.33 million in the prior-year period. Earnings per share (EPS) improved to -$0.06 from -$0.08, with the GAAP EPS missing estimates by $0.01 despite revenue beating expectations by $4.28 million. The EPS of -$0.06 marked a 23.1% improvement in losses compared to the prior year, reflecting progress in cost management.

Price Action

The stock price of The Beauty Health has underperformed in the short term, dropping 7.02% in the latest trading day, 6.19% in the past week, and 12.40% month-to-date.

Post-Earnings Price Action Review

The strategy of buying SKIN shares after a revenue decline in Q4 and holding for 30 days delivered an 89.99% return over three years, underperforming the benchmark by 149.97%. This underperformance was accompanied by a Sharpe ratio of -0.50, signaling high risk, and a maximum drawdown of 95.18%, underscoring the strategy’s susceptibility to market volatility.

CEO Commentary

Pedro Malha, CEO, emphasized progress in transitioning from device sales to recurring consumables revenue, with 1.7% growth in Q4. He outlined 2026 as an “execution year” to stabilize operations and position for growth in 2027, citing disciplined cost management, R&D reinvestment, and churn reduction (1.1% in Q4).

Guidance

The company projected 2026 revenue of $285–305 million, flat year-over-year, with Q1 2026 revenue expected at $63–68 million. Adjusted EBITDA guidance for 2026 stands at $35–45 million, with Q1 guidance of $3.5–5.5 million. Leadership anticipates a return to revenue growth in 2027 as utilization and innovation scale.

Additional News

The Beauty Health announced plans to establish shared service centers to centralize global costs and enhance operational efficiency. Additionally, the company highlighted the launch of its next-generation HydraFacial system in 2028, aiming to drive upgrades and new adoption. Cash and cash equivalents stood at $232.7 million as of December 2025, following a 37% decline in full-year cash due to refinancing and repurchase activities.